Emerging role of nanosuspensions in drug delivery systems

다국어 초록 (Multilingual Abstract)

Rapid advancement in drug discovery process is leading to a number of potential new drug candidates having excellent drug efficacy but limited aqueous solubility. By virtue of the submicron particle size and distinct physicochemical properties, nanosuspension has the potential ability to tackle many formulation and drug delivery issues typically associated with poorly water and lipid soluble drugs. Conventional size reduction equipment such as media mill and high-pressure homogenizers and formulation approaches such as precipitation, emulsion-solvent evaporation, solvent diffusion and microemulsion techniques can be successfully implemented to prepare and scale-up nanosuspensions. Maintaining the stability in solution as well as in solid state, resuspendability without aggregation are the key factors to be considered for the successful production and scale-up of nanosuspensions. Due to the considerable enhancement of bioavailability, adaptability for surface modification and mucoadhesion for drug targeting have significantly expanded the scope of this novel formulation strategy. The application of nanosuspensions in different drug delivery systems such as oral, ocular, brain, topical, buccal, nasal and transdermal routes are currently undergoing extensive research. Oral drug delivery of nanosuspension with receptor mediated endocytosis has the promising ability to resolve most permeability limited absorption and hepatic first-pass metabolism related issues adversely affecting bioavailability. Advancement of enabling technologies such as nanosuspension can solve many formulation challenges currently faced among protein and peptide-based pharmaceuticals.

참고문헌 (Reference)

• 1 Toshiyuki Niwa, "Universal wet-milling technique to prepare oral nanosuspension focused on discovery and preclinical animal studies – Development of particle design method" Elsevier BV 405 (405): 218-227, 2011
• 2 Weder, H. G., "U.S. patent no. 5,726,164"
• 3 Fan Yang, "Transdermal delivery of the anti-rheumatic agent methotrexate using a solid-in-oil nanocarrier" Elsevier BV 82 (82): 158-163, 2012
• 4 Alexander T Florence, "Transcytosis of nanoparticle and dendrimer delivery systems: evolving vistas" Elsevier BV 50 : S69-S89, 2001
• 5 Gabriella Costabile, "Toward repositioning niclosamide for antivirulence therapy of Pseudomonas aeruginosa lung infections:development of inhalable formulations through nanosuspension technology" American Chemical Society (ACS) 12 (12): 2604-2617, 2015
• 6 Hiroyuki Kusuhara, "The Role of P-Glycoprotein and Canalicular Multispecific Organic Anion Transporter in the Hepatobiliary Excretion of Drugs" Elsevier BV 87 (87): 1025-1040, 1998
• 7 Ping-Chang Lin, "Techniques for physicochemical characterization of nanomaterials" Elsevier BV 32 (32): 711-726, 2014
• 8 Arthur A. Noyes, "THE RATE OF SOLUTION OF SOLID SUBSTANCES IN THEIR OWN SOLUTIONS" American Chemical Society (ACS) 19 (19): 930-934, 1897
• 9 Salem HF, "Sustained-release progesterone nanosuspension following intramuscular injection in ovariectomized rats" Informa UK Limited 5 : 943-, 2010
• 10 Tomoyuki Watanabe, "Stabilization of amorphous indomethacin by co-grinding in a ternary mixture" Elsevier BV 241 (241): 103-111, 2002
• 11 Carlos E. Figueroa, "Spray granulation: Importance of process parameters on in vitro and in vivo behavior of dried nanosuspensions" Elsevier BV 85 (85): 1046-1055, 2013
• 12 Samaneh Alaei, "Spray drying of cefixime nanosuspension to form stabilized and fast dissolving powder" Elsevier BV 288 : 241-248, 2016
• 13 J MOSCHWITZER, "Spray coated pellets as carrier system for mucoadhesive drug nanocrystals" Elsevier BV 62 (62): 282-287, 2006
• 14 Himanshu Gupta, "Sparfloxacin-loaded PLGA nanoparticles for sustained ocular drug delivery" Elsevier BV 6 (6): 324-333, 2010
• 15 Maria Malamatari, "Solidification of nanosuspensions for the production of solid oral dosage forms and inhalable dry powders" Informa Healthcare 13 (13): 435-450, 2015
• 16 Alf Lamprecht, "Size-dependent bioadhesion of microand nanoparticulate carriers to the inflamed colonic mucosa" Springer Science and Business Media LLC 18 (18): 788-793, 2001
• 17 Lulu Wang, "Safety of nanosuspensions in drug delivery" Elsevier BV 13 (13): 455-469, 2017
• 18 Claudia Jacobs, "Production and characterization of a budesonide nanosuspension for pulmonary administration" Springer Science and Business Media LLC 19 (19): 189-194, 2002
• 19 Dengning Xia, "Preparation of stable nitrendipine nanosuspensions using the precipitation–ultrasonication method for enhancement of dissolution and oral bioavailability" Elsevier BV 40 (40): 325-334, 2010
• 20 Yuan Zhang, "Preparation of budesonide nanosuspensions for pulmonary delivery: Characterization, in vitro release and in vivo lung distribution studies" Informa UK Limited 44 (44): 285-289, 2014
• 21 Peters K, "Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection" 45 (45): 77-83, 2000
• 22 Mandal, B., "Preparation and physicochemical characterization of Eudragit® RL100 Nanosuspension with potential for ocular delivery of Sulfacetamide" University of Toledo 2010
• 23 J HECQ, "Preparation and in vitro/in vivo evaluation of nano-sized crystals for dissolution rate enhancement of ucb-35440-3, a highly dosed poorly water-soluble weak base" Elsevier BV 64 (64): 360-368, 2006
• 24 P. Kocbek, "Preparation and evaluation of nanosuspensions for enhancing the dissolution of poorly soluble drugs" Elsevier BV 312 (312): 179-186, 2006
• 25 Yan Gao, "Preparation and characterization of intravenously injectable curcumin nanosuspension" Informa UK Limited 18 (18): 131-142, 2010
• 26 Dongsheng Mou, "Potent dried drug nanosuspensions for oral bioavailability enhancement of poorly soluble drugs with pHdependent solubility" Elsevier BV 413 (413): 237-244, 2011
• 27 Khosro Adibkia, "Piroxicam nanoparticles for ocular delivery: Physicochemical characterization and implementation in endotoxin-induced uveitis" Informa UK Limited 15 (15): 407-416, 2008
• 28 William Spreen, "Pharmacokinetics, Safety, and Tolerability With Repeat Doses of GSK1265744 and Rilpivirine (TMC278) Long-Acting Nanosuspensions in Healthy Adults" Ovid Technologies (Wolters Kluwer Health) 67 (67): 487-492, 2014
• 29 G. van 't Klooster, "Pharmacokinetics and Disposition of Rilpivirine (TMC278) Nanosuspension as a Long-Acting Injectable Antiretroviral Formulation" American Society for Microbiology 54 (54): 2042-2050, 2010
• 30 A HANAFY, "Pharmacokinetic evaluation of oral fenofibrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drug" Elsevier BV 59 (59): 419-426, 2007
• 31 Rajamani S, "Pharmacokinetic and tissue distributions of Naringenin and Naringenin Nanosuspension" 12 : 04-, 2019
• 32 Chen Liu, "Oral fast-dissolving films containing lutein nanocrystals for improved bioavailability: formulation development, in vitro and in vivo evaluation" Springer Science and Business Media LLC 18 (18): 2957-2964, 2017
• 33 Indrajit Ghosh, "Optimization of formulation and process parameters for the production of nanosuspension by wet media milling technique: Effect of Vitamin E TPGS and nanocrystal particle size on oral absorption" Elsevier BV 47 (47): 718-728, 2012
• 34 Jin Xie, "Novel redispersible nanosuspensions stabilized by co-processed nanocrystalline cellulose–sodium carboxymethyl starch for enhancing dissolution and oral bioavailability of baicalin" Informa UK Limited 14 : 353-369, 2019
• 35 Irene Rossi, "Nebulized coenzyme Q 10 nanosuspensions: A versatile approach for pulmonary antioxidant therapy" Elsevier BV 113 : 159-170, 2018
• 36 Hull M, "Nanotechnology environmental health and safety: risks, regulation, and management" Elsevier 2018
• 37 V. B. Patravale, "Nanosuspensions: a promising drug delivery strategy" Oxford University Press (OUP) 56 (56): 827-840, 2004
• 38 O. Kayser, "Nanosuspensions for the formulation of aphidicolin to improve drug targeting effects against Leishmania infected macrophages" Elsevier BV 196 (196): 253-256, 2000
• 39 Swarnali Das, "Nanosuspension: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to amphotericin B" Elsevier BV 7 (7): 242-247, 2011
• 40 YK Agrawal, "Nanosuspension: An approach to enhance solubility of drugs" Medknow 2 (2): 81-, 2011
• 41 Lai F, "Nanosuspension improves tretinoin photostability and delivery to the skin" 458 (458): 104-109, 2013
• 42 Elaine Merisko-Liversidge, "Nanosizing: a formulation approach for poorly-water-soluble compounds" Elsevier BV 18 (18): 113-120, 2003
• 43 Filippos Kesisoglou, "Nanosizing — Oral formulation development and biopharmaceutical evaluation" Elsevier BV 59 (59): 631-644, 2007
• 44 Maria Gigliobianco, "Nanocrystals of Poorly Soluble Drugs: Drug Bioavailability and Physicochemical Stability" MDPI AG 10 (10): 134-, 2018
• 45 F. Lai, "Nanocrystals as tool to improve piroxicam dissolution rate in novel orally disintegrating tablets" Elsevier BV 79 (79): 552-558, 2011
• 46 Sumit Kumar, "Nano-amorphous spray dried powder to improve oral bioavailability of itraconazole" Elsevier BV 192 : 95-102, 2014
• 47 Hanna K. Valo, "Multifunctional Hydrophobin: Toward Functional Coatings for Drug Nanoparticles" American Chemical Society (ACS) 4 (4): 1750-1758, 2010
• 48 Abhijit A. Date, "Mucus-penetrating budesonide nanosuspension enema for local treatment of inflammatory bowel disease" Elsevier BV 185 : 97-105, 2018
• 49 Van Eerdenbrugh Bernard, "Microcrystalline cellulose, a useful alternative for sucrose as a matrix former during freeze-drying of drug nanosuspensions – A case study with itraconazole" Elsevier BV 70 (70): 590-596, 2008
• 50 Lai F, "Maltodextrin fast dissolving films for quercetin nanocrystal delivery. A feasibility study" 121 : 217-223, 2015
• 51 Moghimi SM, "Long-circulating and target-specific nanoparticles : theory to practice" 53 (53): 283-318, 2001
• 52 Claire Emilienne Soma, "Investigation of the role of macrophages on the cytotoxicity of doxorubicin and doxorubicin-loaded nanoparticles on M5076 cells in vitro" Elsevier BV 68 (68): 283-289, 2000
• 53 S Liedtke, "Influence of high pressure homogenisation equipment on nanodispersions characteristics" Elsevier BV 196 (196): 183-185, 2000
• 54 Indrajit Ghosh, "Influence of Critical Parameters of Nanosuspension Formulation on the Permeability of a Poorly Soluble Drug through the Skin—A Case Study" Springer Science and Business Media LLC 14 (14): 1108-1117, 2013
• 55 Wang Y, "In vitro and in vivo evaluation of silybin nanosuspensions for oral and intravenous delivery" 21 (21): 155104-, 2010
• 56 Maya George, "Identifying the correlation between drug/stabilizer properties and critical quality attributes (CQAs) of nanosuspension formulation prepared by wet media milling technology" Elsevier BV 48 (48): 142-152, 2013
• 57 O Kayser, "Formulation of amphotericin B as nanosuspension for oral administration" Elsevier BV 254 (254): 73-75, 2003
• 58 Bibaswan Mishra, "Formulation and process optimization of naproxen nanosuspensions stabilized by hydroxy propyl methyl cellulose" Elsevier BV 127 : 300-308, 2015
• 59 Priyanka Rana, "Formulation and evaluation of mucoadhesive buccal films impregnated with carvedilol nanosuspension: a potential approach for delivery of drugs having high first-pass metabolism" Informa UK Limited 20 (20): 224-235, 2013
• 60 Mohamed A. Ibrahim, "Formulation and evaluation of docetaxel nanosuspensions: In-vitro evaluation and cytotoxicity" Elsevier BV 27 (27): 49-55, 2019
• 61 Kanchan Bharti, "Formulation and characterization of fast dissolving oral films containing buspirone hydrochloride nanoparticles using design of experiment" Elsevier BV 49 : 420-432, 2019
• 62 He W, "Formulating food protein-stabilized indomethacin nanosuspensions into pellets by fluid-bed coating technology : physical characterization, redispersibility, and dissolution" 8 : 3119-, 2013
• 63 Ali Ahmadi Tehrani, "Formation of nanosuspensions in bottom-up approach: theories and optimization" Springer Science and Business Media LLC 27 (27): 451-473, 2019
• 64 Arpansiree Wongmekiat, "Formation of fine drug particles by cogrinding with cyclodextrins. I The use of β-cyclodextrin anhydrate and hydrate" Springer Science and Business Media LLC 19 (19): 1867-1872, 2002
• 65 Wang L, "Folate-targeted docetaxel-lipid-based-nanosuspensions for active-targeted cancer therapy" Informa UK Limited 7 : 3281-, 2012
• 66 Jan P. Möschwitzer, "Factors influencing the release kinetics of drug nanocrystal-loaded pellet formulations" Informa UK Limited 39 (39): 762-769, 2012
• 67 Xin Zhang, "Exploration of nanocrystal technology for the preparation of lovastatin immediate and sustained release tablets" Elsevier BV 50 : 107-112, 2019
• 68 Rahul B. Chavan, "Evaluation of the inhibitory potential of HPMC, PVP and HPC polymers on nucleation and crystal growth" Royal Society of Chemistry (RSC) 6 (6): 77569-77576, 2016
• 69 Li Jun, "Enhanced oral bioavailability of fluvastatin by using nanosuspensions containing cyclodextrin" Informa UK Limited 12 : 3491-3499, 2018
• 70 Claudio Bucolo, "Enhanced ocular antiinflammatory activity of ibuprofen carried by an eudragit RS100®nanoparticle suspension" S. Karger AG 34 (34): 319-323, 2002
• 71 Veronika Braig, "Enhanced dissolution of naproxen from pure-drug, crystalline nanoparticles: A case study formulated into spray-dried granules and compressed tablets" Elsevier BV 554 : 54-60, 2019
• 72 Anh Nguyen Quynh Phan, "Efficient Method for Preparation of Rutin Nanosuspension Using Chitosan and Sodium Tripolyphosphate Crosslinker" American Scientific Publishers 19 (19): 974-978, 2019
• 73 Bhavna, "Donepezil nanosuspension intended for nose to brain targeting: In vitro and in vivo safety evaluation" Elsevier BV 67 : 418-425, 2014
• 74 Li HY, "Dispersibility of spray-dried formulations for pulmonary drug delivery" Oxford University Press (OUP) 56 (56): S10-, 2004
• 75 Ankita D. Chonkar, "Development of fast dissolving oral films containing lercanidipine HCl nanoparticles in semicrystalline polymeric matrix for enhanced dissolution and ex vivo permeation" Elsevier BV 103 : 179-191, 2016
• 76 Veerawat Teeranachaideekul, "Development of ascorbyl palmitate nanocrystals applying the nanosuspension technology" Elsevier BV 354 (354): 227-234, 2008
• 77 Thuy Hoang, "Development of a mucoinert progesterone nanosuspension for safer and more effective prevention of preterm birth" Elsevier BV 295 : 74-86, 2019
• 78 Bin Du, "Development and characterization of glimepiride nanocrystal formulation and evaluation of its pharmacokinetic in rats" Informa UK Limited 20 (20): 25-33, 2012
• 79 Om Prakash Sharma, "Design of experiment approach in development of febuxostat nanocrystal: Application of Soluplus® as stabilizer" Elsevier BV 302 : 396-405, 2016
• 80 Andreas Lemke, "Delivery of amphotericin B nanosuspensions to the brain and determination of activity against Balamuthia mandrillaris amebas" Elsevier BV 6 (6): 597-603, 2010
• 81 Shery Jacob, "Cyclodextrin complexes: Perspective from drug delivery and formulation" Wiley 79 (79): 201-217, 2018
• 82 Lutz Horster, "Conversion of PLGA nanoparticle suspensions into solid dosage forms via fluid bed granulation and tableting" Elsevier BV 134 : 77-87, 2019
• 83 K. H. Ziller, "Conteol of Crystal Growth in Drug Suspensions: 1) Design of a Conteol Unit and Application to Acetaminophen Suspensions)" Informa UK Limited 14 (14): 2341-2370, 2008
• 84 Keith P. Johnston, "Concentrated Dispersions of Equilibrium Protein Nanoclusters That Reversibly Dissociate into Active Monomers" American Chemical Society (ACS) 6 (6): 1357-1369, 2012
• 85 Isabel Behrens, "Comparative uptake studies of bioadhesive and non-bioadhesive nanoparticles in human intestinal cell lines and rats: the effect of mucus on particle adsorption and transport" Springer Science and Business Media LLC 19 (19): 1185-1193, 2002
• 86 R.H. Müller, "Buparvaquone mucoadhesive nanosuspension: preparation, optimisation and long-term stability" Elsevier BV 237 (237): 151-161, 2002
• 87 Tingjie Yin, "Biological evaluation of PEG modified nanosuspensions based on human serum albumin for tumor targeted delivery of paclitaxel" Elsevier BV 83 : 79-87, 2016
• 88 Sonali Bose, "Application of spray granulation for conversion of a nanosuspension into a dry powder form" Elsevier BV 47 (47): 35-43, 2012
• 89 Anu Nair, "Application of quality by design for optimization of spray drying process used in drying of Risperidone nanosuspension" Elsevier BV 342 : 156-165, 2019
• 90 G.J Vergote, "An oral controlled release matrix pellet formulation containing nanocrystalline ketoprofen" Elsevier BV 219 (219): 81-87, 2001
• 91 Shigeru Kohno, "Amphotericin B encapsulated in polyethylene glycol-immunoliposomes for infectious diseases" Elsevier BV 24 (24): 325-329, 1997
• 92 Jonghwi Lee, "Amphiphilic amino acid copolymers as stabilizers for the preparation of nanocrystal dispersion" Elsevier BV 24 (24): 441-449, 2005
• 93 Thao Truong-Dinh Tran, "Amorphous isradipine nanosuspension by the sonoprecipitation method" Elsevier BV 474 (474): 146-150, 2014
• 94 Bruce J. Aungst, "Absorption Enhancers: Applications and Advances" Springer Science and Business Media LLC 14 (14): 10-18, 2012
• 95 Hongyu Piao, "A Novel Solid-in-oil Nanosuspension for Transdermal Delivery of Diclofenac Sodium" Springer Science and Business Media LLC 25 (25): 896-901, 2008